Abstract
We conducted a systematic review to assess the evidence for specific effects of cannabis on impulsivity, disinhibition and motor control. The review had a specific focus on neuroimaging findings associated with acute and chronic use of the drug and covers literature published up until May 2012. Seventeen studies were identified, of which 13 met the inclusion criteria; three studies investigated acute effects of cannabis (1 fMRI, 2 PET), while six studies investigated non-acute functional effects (4 fMRI, 2 PET), and four studies investigated structural alterations. Functional imaging studies of impulsivity studies suggest that prefrontal blood flow is lower in chronic cannabis users than in controls. Studies of acute administration of THC or marijuana report increased brain metabolism in several brain regions during impulsivity tasks. Structural imaging studies of cannabis users found differences in reduced prefrontal volumes and white matter integrity that might mediate the abnormal impulsivity and mood observed in marijuana users. To address the question whether impulsivity as a trait precedes cannabis consumption or whether cannabis aggravates impulsivity and discontinuation of usage more longitudinal study designs are warranted.
Keywords: Cannabis, marijuana, cannabinoids, impulsivity, inhibition, neuroimaging, magnetic resonance imaging, MRI, fMRI.
Current Pharmaceutical Design
Title:Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings
Volume: 20 Issue: 13
Author(s): Johannes Wrege, Andre Schmidt, Anna Walter, Renata Smieskova, Kerstin Bendfeldt, Ernst-Wilhelm Radue, Undine E. Lang and Stefan Borgwardt
Affiliation:
Keywords: Cannabis, marijuana, cannabinoids, impulsivity, inhibition, neuroimaging, magnetic resonance imaging, MRI, fMRI.
Abstract: We conducted a systematic review to assess the evidence for specific effects of cannabis on impulsivity, disinhibition and motor control. The review had a specific focus on neuroimaging findings associated with acute and chronic use of the drug and covers literature published up until May 2012. Seventeen studies were identified, of which 13 met the inclusion criteria; three studies investigated acute effects of cannabis (1 fMRI, 2 PET), while six studies investigated non-acute functional effects (4 fMRI, 2 PET), and four studies investigated structural alterations. Functional imaging studies of impulsivity studies suggest that prefrontal blood flow is lower in chronic cannabis users than in controls. Studies of acute administration of THC or marijuana report increased brain metabolism in several brain regions during impulsivity tasks. Structural imaging studies of cannabis users found differences in reduced prefrontal volumes and white matter integrity that might mediate the abnormal impulsivity and mood observed in marijuana users. To address the question whether impulsivity as a trait precedes cannabis consumption or whether cannabis aggravates impulsivity and discontinuation of usage more longitudinal study designs are warranted.
Export Options
About this article
Cite this article as:
Wrege Johannes, Schmidt Andre, Walter Anna, Smieskova Renata, Bendfeldt Kerstin, Radue Ernst-Wilhelm, Lang E. Undine and Borgwardt Stefan, Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings, Current Pharmaceutical Design 2014; 20 (13) . https://dx.doi.org/10.2174/13816128113199990428
DOI https://dx.doi.org/10.2174/13816128113199990428 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Neuroactive Steroids in Depressive Disorders
Current Psychiatry Reviews Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Synthesis of Novel 2-(Methylthio)benzo[g][1,2,4]triazolo[1,5-a]quinazolin- 5-(4H)-one and its Derivatives
Letters in Organic Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Polyoxometalates in Biomedicine: Update and Overview
Current Medicinal Chemistry Medication Management Issues in Old Age: A Call for Submissions to Current Clinical Pharmacology
Current Clinical Pharmacology Editorial [Hot Topic: Anti-Aging Compounds (Guest Editor: Bela Torok)]
Current Bioactive Compounds Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Current Trends on Antipsychotics: Focus on Asenapine
Current Medicinal Chemistry Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Chemokine Receptors as Anti-Retroviral Targets
Current Drug Targets